🇯🇵·14h agoIndustry
PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Adults with Resectable Muscle-Invasive Bladder Cancer
Publisher
A
Astellas Pharma
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Astellas Pharma
- Region
- Japan
- Scope
- Industry
- Published
- September 18, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on newsroom.astellas.com
Leave the platform to read the original full article on the publisher site.
Source: Astellas Pharma
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/3h ago
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Merck & Co. (MSD) News/3h ago
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Roche Newsroom/3h ago
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Merck & Co. (MSD) News/3h ago